Key result
IV epoprostenol for PAH outlines feasibility and clinical challenges in initial observational experience.
Why the study?
There is a lack of data on the feasibility and tolerability of intravenous epoprostenol therapy for pulmonary arterial hypertension in Singapore.
Is intravenous epoprostenol therapy feasible and tolerable for treating pulmonary arterial hypertension in Singapore?
Observational
Is intravenous epoprostenol therapy feasible and tolerable for treating pulmonary arterial hypertension in Singapore?
This study describes the initial clinical experience, feasibility, and tolerability of using intravenous epoprostenol for pulmonary arterial hypertension in a Singaporean population.
Answers are grounded in this paper and cite their sources.
Initial Singapore experience with IV epoprostenol in PAH highlights implementation challenges; leaves open efficacy and safety in Asian populations.
Pulmonary arterial hypertension (PAH) is a progressive disease characterised by significant morbidity and mortality. Intravenous (IV) epoprostenol (Veletri, Johnson & Johnson, US), a prostacyclin analogue, has been shown to improve exercise tolerance, PAH symptoms, haemodynamics and survival.1,2 However, there is a lack of data on feasibility and tolerability of this therapy in Singapore. A previous study examined the use of selexipag, an oral prostacyclin analogue, in a Singapore population.3 We aimed to describe the first Singapore experience of initiating and maintaining IV epoprostenol therapy for treating PAH patients in Singapore, and highlight the various issues and challenges encountered.
No takes yet. Share an insight, caveat, or question.
Yap et al. (2024) conducted an observational in Pulmonary arterial hypertension. Intravenous epoprostenol was evaluated. The abstract describes the initial experience and challenges of using intravenous epoprostenol for pulmonary arterial hypertension in Singapore, but reports no quantitative outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: